Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00868088 · ClinicalTrials.gov registry record · Phase 4
Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip
A Phase 4 study of Actinic Cheilitis and Squamous Cell Carcinoma In-situ (SCC-is), sponsored by Tufts Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT00868088: Completed Phase 4 study of Actinic Cheilitis and Squamous Cell Carcinoma In-situ (SCC-is), sponsored by Tufts Medical Center.
NCT00868088 is a Phase 4 study of Actinic Cheilitis and Squamous Cell Carcinoma In-situ (SCC-is) that has completed, run by Tufts Medical Center. The registered enrollment target is 34 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00868088, a Phase 4 study of Actinic Cheilitis and Squamous Cell Carcinoma In-situ (SCC-is), has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
Our study is designed to evaluate the efficacy of photodynamic therapy (PDT) for treatment of actinic cheilitis (AC) and as an adjunct to Mohs surgery for squamous cell carcinoma (SCC) on the lips. This study will utilize an FDA approved PDT modality (DUSA, Inc., Wilmington, MA 01887) using topical 5-amino-levulinic acid (ALA) for photosensitization followed by exposure to a Blu-U light source emitting 405-420nm wavelength light.
Conditions Studied
Interventions
- PROCEDURE PDT prior to Mohs surgery
Study Locations (1)
Massachusetts
- Tufts Medical Center, Department of Dermatology - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-09 |
| Phase | Phase 4 |
What the finished NCT00868088 record still lists
NCT00868088 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 5 conditions, with Actinic Cheilitis appearing as the primary indexed condition, and to 1 intervention - of which PDT prior to Mohs surgery is the first listed.
NCT00868088 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00868088 about?
NCT00868088 is a clinical study titled "Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip". Our study is designed to evaluate the efficacy of photodynamic therapy (PDT) for treatment of actinic cheilitis (AC) and as an adjunct to Mohs surgery for squamous cell carcinoma (SCC) on the lips. This study will utilize an FDA approved PDT modality (DUSA, Inc., Wilmington, MA 01887) using topical ...
What is the current status of trial NCT00868088?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2009-07. Estimated completion is 2010-09.
What conditions does trial NCT00868088 study?
This clinical trial studies the following conditions: Actinic Cheilitis, Squamous Cell Carcinoma In-situ (SCC-is), Squamous Cell Carcinoma (SCC), Photodynamic Therapy (PDT), Mohs Surgery.
What interventions are being tested in trial NCT00868088?
The interventions under investigation include: PDT prior to Mohs surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00868088?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00868088 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00868088's enrollment target sits among peer trials
34 1520th of 2000 higher than 473 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia